CARA: Cara Therapeutics, Inc Price to Sales

Corporate company logo of Cara Therapeutics Inc. (CARA)

Cara Therapeutics, Inc. (CARA) is stagnating due to failed tests and requires a portfolio update. However, niche dominance in the therapy of dialysis patients allows the company to maintain premium pricing. An expansion strategy via B2B partnerships aims for market capture. The current price-to-sales ratio on the GURU.Markets system summary chart reflects sales dynamics, where 15.10 serves as the current parameter value.

CARA: Cara Therapeutics, Inc. P/S Multiple 07/04/2022 - 05/09/2026

Analytical breakdowns for Cara Therapeutics Inc. (CARA)

Summary company analytics:CARA Cara Therapeutics, Inc
Flagship merchandise of Cara Therapeutics

The P/S multiple determines the market value of a business relative to its generated revenue, allowing for an assessment of asset monetization efficiency and the identification of "value trap" risks during price undervaluation. For Cara Therapeutics, Inc. (CARA), the decline in the price-to-sales ratio reflects market skepticism stemming from the termination of clinical phases and the loss of its partner network within the nephrology drug segment.

Who Cara Therapeutics, Inc. competes with

BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price to Sales Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - P/S Multiple|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|Price-to-Revenue Coefficient Harmony Biosciences|Biohaven Ltd - Market Cap to Revenue|P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Market Cap to Revenue|Price-to-Revenue Coefficient Praxis Corp PRAX|AVXL: P/S Multiple|CBLL (ceribell.com) - Price-to-Revenue Ratio|PRTA (Prothena Corporation) - P/S Multiple|Market Cap to Revenue alector.com (ALEC)|Price-to-Revenue Ratio Annexon, Inc. (ANNX)|OMER - Price to Sales|P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Price to Sales|Voyager Therapeutics Inc - P/S Multiple|Neumora (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|TVGN - Price-to-Revenue Coefficient|ACOG (Alpha Cognition Inc) - P/S Multiple|Market Cap to Revenue cogrx.com (CGTX)|Price-to-Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Price-to-Revenue Coefficient Cassava Sciences|P/S Multiple ASRT (Assertio Holdings)|COYA - Market Cap to Revenue|vistagen.com - P/S Multiple|OVID: Price-to-Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Revenue Ratio|CervoMed Inc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alterity Therapeutics Limited|clene.com (CLNN) - Price-to-Revenue Coefficient|Market Cap to Revenue PEPG (PepGen Inc)|P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Revenue Ratio|Grace Tx - P/S Multiple|AIFF (Firefly Neuroscience Inc) - Market Cap to Revenue Ratio|KLTO: P/S Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - P/S Multiple|Price-to-Revenue Ratio Reviva Pharmaceuticals, Inc.|Market Cap to Revenue metaviatx.com (MTVA)|P/S Multiple NRXS|HSDT - Price to Sales|Passage Bio, Inc. - Market Cap to Revenue|bionomics.com.au (NEUP) - Price to Sales|Minerva - P/S Multiple|Market Capitalization-to-Revenue Ratio ATHA (Athira Pharma Inc)|ADXN: P/S Multiple|Market Cap to Revenue Ratio ALZN|CYCN (Cyclerion Therapeutics Inc.) - P/S Multiple|PTIX (Protagenic Therapeutics) - Market Cap to Sales Volume|P/S Multiple KTTA|Price-to-Revenue Coefficient Cortigent|P/S Multiple ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Price-to-Revenue Ratio|chromocell.com - P/S Multiple|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|Price to Sales Longboard Pharmaceuticals, Inc. (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue